Cedars-Sinai Discovery May Aid Doctors in Diagnosing At-risk Patients Before Symptoms Appear
A team led by a Cedars-Sinai physician-scientist has discovered a biomarker—a protein found in the blood—for the most common type of heart failure, a new study published today in JAMA Cardiology shows.
Heart failure with preserved ejection fraction (HFpEF) affects more than 6.5 million Americans each year. And now, thanks to the discovery of the first-ever biomarker for HFpEF, a simple blood test can reveal whether a patient’s heart is not making enough of an important protein. If the protein levels are decreased, the biomarker signal increases and physicians will be able to diagnose heart failure sooner, prescribe corrective medicines and prevent further disease progression.
“By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed,” said Robin Shaw, MD, PhD, the Wasserman Endowed Chair in Cardiology and professor of Medicine at the Smidt Heart Institute at Cedars-Sinai and principal investigator on the study. “Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed.”
Heart failure with preserved ejection fraction is a condition where the heart can contract, but has problems relaxing—limiting the heart’s ability to fill with blood between each beat—and therefore lowers the amount of blood moving forward with each contraction. Prior to the discovery of the biomarker, clinicians had to wait for patients to have symptoms to make a diagnosis of HFpEF and had to use an echocardiogram that measured how well the heart relaxed. There was no method to gauge the health of the heart muscle before symptoms developed or determine the severity of disease once symptoms were present.
The biomarker—named cBIN1 Score, or CS for short—allows doctors to measure muscle deterioration and measure a protein that regulates the heart’s ability to both contract and relax. As the protein decreases, CS increases, serving as an indication of onset heart failure. The CS biomarker can be measured using a simple blood draw.
This discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician. This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.
Eduardo Marbán, MD, PhD, director, Smidt Heart Institute
The CS biomarker is designed to be used in an outpatient clinic setting. For patients with known HFpEF, doctors can draw a CS level and use it to both guide current care, including medication adjustments, and predict the chances of a patient being admitted to the hospital in the next 12 months.
“More broadly, this discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. “This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.”
Symptoms of heart failure typically appear as fatigue, fluid weight gain, leg swelling and shortness of breath. Heart failure with preserved ejection fraction is typically diagnosed in elderly people or those living with high blood pressure, diabetes, elevated cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes. Its prevalence is projected to rise drastically over the coming decades. Previous studies have shown that women represent the majority of patients diagnosed with the disease.
As next steps, Cedars-Sinai researchers plan on identifying specialty populations in which the CS biomarker could be useful, including sex-based differences, those who have undergone a heart transplant or valve replacement, as well as individuals with no known heart disease or risk factors.
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failureon October 8, 2020 at 6:30 am
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Oct. 08, 2020-- Amgen, Cytokinetics, Incorporated and Servier today announced topline results from GALACTIC-HF, a Phase 3 ...
- Amgen, Cytokinetics Heart-Failure Study Hits Main Endpoint, Misses Secondaryon October 8, 2020 at 6:09 am
Amgen Inc., Cytokinetics Inc. and Laboratoires Servier SA on Thursday said a pivotal phase 3 study of omecamtiv mecarbil in patients with heart failure met its primary composite endpoint but missed ...
- Cytokinetics/Amgen omecamtiv mecarbil shows mixed results in heart failure study; CYTK down 37%on October 8, 2020 at 5:52 am
(NASDAQ:CYTK) slumps 37% premarket, Amgen (NASDAQ:AMGN) down 3% after announcing topline results from GALACTIC-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with ...
- TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patientson October 8, 2020 at 5:07 am
The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival ...
- Heart failure drugs market Valuable Growth Prospects, Size, Share, Demand and Current Trends Analysison October 7, 2020 at 5:32 pm
Global Heart Failure Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025[88 pages ...
- How Do Hospitalizations for Heart Failure Differ Before vs During the COVID-19 Era?on October 7, 2020 at 2:37 pm
Patients hospitalized for acute heart failure during the coronavirus disease 2019 (COVID-19) pandemic had more advanced disease and were more symptomatic, according to study results out of Australia.
- CHF Solutions Announces Data Demonstrating Benefit of Aquadex Therapy for Treatment of Heart Failure and COVID-19on October 7, 2020 at 6:00 am
CHF Solutions, a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced data from a retrospective study and a case study supporting the ...
- General practice doctors failing to provide optimal treatment for heart disease patientson October 6, 2020 at 5:13 am
General practice management of patients with cardiovascular disease (CVD) is "suboptimal," with only 57% of patients with established CVD prescribed the guideline-recommended treatments, according ...
- Virtual Heart Failure Care No Substitute for the Face-to-Face Visit?on October 5, 2020 at 5:05 pm
At a tertiary care heart failure clinic, guideline-directed medical therapy (GDMT) titration overall decreased from in-person visits before COVID (Feb. 18 to March 13 this year) to virtual visits ...
via Bing News